Generic Latanoprost: An Equivalent Comparison Open-labelled Study

Not Applicable

• Conditions: GlaucomaOcular hypertensionCurrently using original latanoprost; Glaucoma; Ocular hypertention; Prostaglandins analogue; Latanoprost; Generic drug; Intraocular pressure

• Registration Number: TCTR20180115001
• Lead Sponsor: Bausch & Lomb Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-15
• Study Completion: 2019-01-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients who have been diagnosed with any type of glaucoma or ocular hypertension
No history of cataract within the last 3 months
Using the original latanoprost (Xalatan) for more than 4 weeks

Exclusion Criteria

History of any type of intraocular pressure reduction surgery
History of laser peripheral iridotomy within the last 3 months
History of ocular trauma
Currently on more than 1 antihypertensive eyedrops apart from latanoprost
History of any irregular ocular surface condition
Currently on glucocorticoid eyedrops

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intraocular pressure reduction at 4 and 12 week after start the intervention Goldmann applanation tonometer

Secondary Outcome Measures

Name	Time	Method
Safety at 4 and 12 week after start the intervention Physical examination, patients' comment